703 related articles for article (PubMed ID: 28629427)
21. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.
Harris AR; Perez MJ; Munson JM
BMC Cancer; 2018 Jul; 18(1):718. PubMed ID: 29976154
[TBL] [Abstract][Full Text] [Related]
22. Curcumin inhibits lymphangiogenesis in vitro and in vivo.
Wang W; Sukamtoh E; Xiao H; Zhang G
Mol Nutr Food Res; 2015 Dec; 59(12):2345-54. PubMed ID: 26375757
[TBL] [Abstract][Full Text] [Related]
23. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
24. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells.
Zhuo W; Luo C; Wang X; Song X; Fu Y; Luo Y
J Pathol; 2010 Nov; 222(3):249-60. PubMed ID: 20814900
[TBL] [Abstract][Full Text] [Related]
25. A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities.
Xu Y; Lu W; Yang P; Peng W; Wang C; Li M; Li Y; Li G; Meng N; Lin H; Kan L; Wang S; Yang S; Yu L; Zhao Y
BMC Cancer; 2015 Jul; 15():525. PubMed ID: 26187637
[TBL] [Abstract][Full Text] [Related]
26. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models.
Ekshyyan O; Moore-Medlin TN; Raley MC; Sonavane K; Rong X; Brodt MA; Abreo F; Alexander JS; Nathan CA
BMC Cancer; 2013 Jul; 13():320. PubMed ID: 23815869
[TBL] [Abstract][Full Text] [Related]
27. Delphinidin is a novel inhibitor of lymphangiogenesis but promotes mammary tumor growth and metastasis formation in syngeneic experimental rats.
Thiele W; Rothley M; Teller N; Jung N; Bulat B; Plaumann D; Vanderheiden S; Schmaus A; Cremers N; Göppert B; Dimmler A; Eschbach V; Quagliata L; Thaler S; Marko D; Bräse S; Sleeman JP
Carcinogenesis; 2013 Dec; 34(12):2804-13. PubMed ID: 23975834
[TBL] [Abstract][Full Text] [Related]
28. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
Huang B; Lu Y; Gui M; Guan J; Lin M; Zhao J; Mao Q; Lin J
Biomed Pharmacother; 2021 May; 137():111331. PubMed ID: 33578235
[TBL] [Abstract][Full Text] [Related]
29. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
Nandi P; Girish GV; Majumder M; Xin X; Tutunea-Fatan E; Lala PK
BMC Cancer; 2017 Jan; 17(1):11. PubMed ID: 28056899
[TBL] [Abstract][Full Text] [Related]
30. The marine fungal metabolite, AD0157, inhibits angiogenesis by targeting the Akt signaling pathway.
García-Caballero M; Cañedo L; Fernández-Medarde A; Medina MÁ; Quesada AR
Mar Drugs; 2014 Jan; 12(1):279-99. PubMed ID: 24441613
[TBL] [Abstract][Full Text] [Related]
31. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer.
Shimizu K; Kubo H; Yamaguchi K; Kawashima K; Ueda Y; Matsuo K; Awane M; Shimahara Y; Takabayashi A; Yamaoka Y; Satoh S
Cancer Sci; 2004 Apr; 95(4):328-33. PubMed ID: 15072591
[TBL] [Abstract][Full Text] [Related]
32. Fucoxanthin inhibits tumour-related lymphangiogenesis and growth of breast cancer.
Wang J; Ma Y; Yang J; Jin L; Gao Z; Xue L; Hou L; Sui L; Liu J; Zou X
J Cell Mol Med; 2019 Mar; 23(3):2219-2229. PubMed ID: 30648805
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.
He Y; Rajantie I; Pajusola K; Jeltsch M; Holopainen T; Yla-Herttuala S; Harding T; Jooss K; Takahashi T; Alitalo K
Cancer Res; 2005 Jun; 65(11):4739-46. PubMed ID: 15930292
[TBL] [Abstract][Full Text] [Related]
34. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
[TBL] [Abstract][Full Text] [Related]
35. Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: in Vitro Evidence.
Manetti M; Romano E; Rosa I; Fioretto BS; Guiducci S; Bellando-Randone S; Pigatto E; Cozzi F; Ibba-Manneschi L; Matucci-Cerinic M
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817940
[TBL] [Abstract][Full Text] [Related]
36. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
[TBL] [Abstract][Full Text] [Related]
37. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis.
Lahdenranta J; Hagendoorn J; Padera TP; Hoshida T; Nelson G; Kashiwagi S; Jain RK; Fukumura D
Cancer Res; 2009 Apr; 69(7):2801-8. PubMed ID: 19318557
[TBL] [Abstract][Full Text] [Related]
38. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.
Goldman J; Rutkowski JM; Shields JD; Pasquier MC; Cui Y; Schmökel HG; Willey S; Hicklin DJ; Pytowski B; Swartz MA
FASEB J; 2007 Apr; 21(4):1003-12. PubMed ID: 17210781
[TBL] [Abstract][Full Text] [Related]
39. The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.
Tutunea-Fatan E; Majumder M; Xin X; Lala PK
Mol Cancer; 2015 Feb; 14():35. PubMed ID: 25744065
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 matrix protein p17 promotes lymphangiogenesis and activates the endothelin-1/endothelin B receptor axis.
Caccuri F; Rueckert C; Giagulli C; Schulze K; Basta D; Zicari S; Marsico S; Cervi E; Fiorentini S; Slevin M; Guzman CA; Caruso A
Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):846-56. PubMed ID: 24482377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
